Reports of spontaneous regressions of metastases and the demonstration of tumor-reactive cytotoxic T lymphocytes indicate the importance of the host's immune system in controlling the devastating course of metastatic renal cell carcinoma1,2,3. Recent research indicates that immunization with hybrids of tumor and antigen presenting cells results in protective immunity and rejection of established tumors in various rodent models4,5,6,7,8. Here, we present a hybrid cell vaccination study of 17 patients. Using electrofusion techniques5, we generated hybrids of autologous tumor and allogeneic dendritic cells that presented antigens expressed by the tumor in concert with the co-stimulating capabilities of dendritic cells. After vaccination, and with a mean follow-up time of 13 months, four patients completely rejected all metastatic tumor lesions, one presented a ‘mixed response’, and two had a tumor mass reduction of greater 50%. We also demonstrate induction of HLA-A2-restricted cytotoxic T cells reactive with the Muc1 tumor-associated antigen and recruitment of CD8+ lymphocytes into tumor challenge sites. Our data indicate that hybrid cell vaccination is a safe and effective therapy for renal cell carcinoma and may provide a broadly applicable strategy for other malignancies with unknown antigens.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Jayson, G.C., Middleton, M., Lee, S.M., Ashcroft, L. & Thatcher, N. A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer. Br. J. Cancer 78, 366–369 (1998).
Lokich, J. Spontaneous regression of metastatic renal cancer. Case report and literature review. Am. J. Clin. Oncol. 20, 416– 418 (1997).
Jantzer, P. & Schendel, D.J. Human renal cell carcinoma antigen-specific CTLs: antigen-driven selection and long-term persistence in vivo. Cancer Res. 58, 3078–3086 (1998).
Guo, Y. et al. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science 263, 518– 520 (1994).
Stuhler, G. & Walden, P. Recruitment of helper T cells for induction of tumor rejection by cytolytic T lymphocytes. Cancer Immunol. Immunother 39, 342–345 (1994).
Gong, J., Chen, D., Kashiwaba, M. & Kufe, D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Med. 3, 558–561 ( 1997).
Wang, J., Saffold, S., Cao, X., Krauss, J. & Chen, W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J. Immunol. 161, 5516–5524 ( 1998).
Gong, J. et al. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc. Natl. Acad. Sci. USA 95, 6279– 6283 (1998).
Kugler, A. et al. Autologous and allogenic hybrid cell vaccine in patients with metastatic renal cell carcinoma. Br. J. Urol. 82, 487–493 (1998).
Banchereau, J. & Steinman, R.M. Dendritic cells and the control of immunity. Nature 392, 245–252 (1998).
Stuhler, G. et al. Immune regulatory loops determine productive interactions within human T lymphocyte-dendritic cell clusters. Proc. Natl. Acad. Sci. USA 96, 1532–1535 (1999).
Brossart, P. et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93, 4309–4317 ( 1999).
Brossart, P. et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res. 58, 732–736 ( 1998).
Fujita, K. et al. Expression of MUC1 mucins inversely correlate with post-surgical survival of renal cell carcinoma patients. Br. J. Cancer 80, 301–308 (1999).
Anichini, A., Mazzocchi, A., Fossati, G. & Parmiani, G. Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction. J. Immunol. 142, 3692– 3701 (1989).
Sallusto, F. & Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179, 110– 1118 (1994).
The authors thank M. Striepe. The general support of the blood bank, departments of radiology and radiotherapy and the HLA laboratory of the University of Göttingen is acknowledged.
About this article
Cite this article
Kugler, A., Stuhler, G., Walden, P. et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell–dendritic cell hybrids. Nat Med 6, 332–336 (2000). https://doi.org/10.1038/73193
International Journal of Molecular Sciences (2021)
Nanovaccine‐Based Strategies to Overcome Challenges in the Whole Vaccination Cascade for Tumor Immunotherapy
Scientific Reports (2020)
Copresentation of Tumor Antigens and Costimulatory Molecules via Biomimetic Nanoparticles for Effective Cancer Immunotherapy
Nano Letters (2020)
Localized hydrogel delivery of dendritic cells for attenuation of multiple sclerosis in a murine model
Journal of Biomedical Materials Research Part A (2020)